Towards Healthcare
Scaffold Technology Market Size, Growth & Trend Analysis

Scaffold Technology Market Size & Volume Production

The global scaffold technology market was estimated at US$ 2.66 billion in 2025 and is projected to grow to US$ 8.58 billion by 2030, rising at a compound annual growth rate (CAGR) of 5.10% from 2024 to 2034. In 2023, North America led the market with a 41% share, while the Asia Pacific region is projected to experience the fastest growth throughout the forecast period. The hydrogels segment was the largest by type in 2023, but nanofiber-based scaffolds are expected to grow at the highest CAGR from 2024 to 2034.

Scaffold Technology Market Size, Shares and Segmental Growth

The global scaffold technology market was estimated at US$ 2.05 billion in 2023 and is projected to grow to US$ 8.58 billion by 2034, rising at a compound annual growth rate (CAGR) of 13.9% from 2024 to 2034. Scaffolds are in high demand due to the growing research and development around stem cells and growing organs in laboratories for transplanting. It is also in high demand for studying diseases and therapeutic drugs without using any animal models and/or humans as test subjects.

Scaffold Technology Market Revenue 2023 to 2034 (USD Billion)

Unlock Infinite Advantages: Subscribe to Annual Membership

Major Key Insights of the Scaffold Technology Market

  • North America dominated the market share by 41% in 2023.
  • Asia Pacific is expected to grow at the fastest rate during the forecast period.
  • By type, the hydrogels segment held the majority of the market share in 2023.
  • By type, the nanofiber-based scaffolds segment is anticipated to grow at the fastest CAGR during 2024-2034.
  • By disease, the orthopedics, musculoskeletal, and spine segment dominated the scaffold technology market in 2023.
  • The neurology segment is estimated to grow at the fastest rate during the predicted period.
  • By application, the stem cell therapy, regenerative medicine, and tissue engineering segment emerged as the dominant segment in 2023.
  • By end-use, the biotechnology & pharmaceutical companies segment held the largest share of the scaffold technology market in 2023.

Scaffold Technology Market: Tissue/Organ Repairing

Scaffolds are like molds made out of polymers, PGA, PEG, PLGA, PLC, PLA, and propylene fumarate for the purpose of tissue engineering. Tissue engineering is a process of developing monolayers, spheroids, and organoids using different human cells. Tissue engineering has turned out to be an important field for the development of biological substitutes for restoring, replacing, and regenerating defective tissues. Scaffolds play a significant role in the development of organoids because, without scaffolds, it is not possible to develop a properly structured organoid. The scaffold technology market is growing due to the growing demand for drug development, drug discovery, tissue and organ transplant, and stem cell research.

How can AI Improve the Scaffold Technology Market?

Technological advancements have played an important role in the growth and development of the tissue engineering industry and scaffold technology market. The integration of AI and machine learning has become crucial in providing support during the entire process of scaffold building and tissue engineering. In scaffold development, AI and machine learning can be used to select materials and design by analyzing existing data. In the case of tissue engineering, AI and machine learning are used in biomaterial design, computational modeling, and cell culture optimizations. Currently, the organoids developed using scaffolds have certain issues. These issues can be resolved using AI data analysis and AI suggestions to improve the current technology.

Top Companies in the Scaffold Technology Market

  • Thermo Fisher Scientific, Inc.
  • CytoNest Inc.
  • Pelobiotech
  • Merck KGaA
  • 3D Biotek LLC
  • Tempo Therapeutics
  • Sanofi
  • Medtronic
  • Becton, Dickinson, and Company
  • Tecan Trading AG
  • Molecular Matrix, Inc.
  • REPROCELL Inc.
  • 4titude
  • Akron Biotech
  • Vericel Corporation
  • Allergan
  • Avacta Life Sciences Limited.
  • Corning Incorporated
  • Matricel GmbH
  • NuVasive, Inc.

Innovation by CytoNest in the Scaffold Technology Market

Company Name CytoNest Inc. 
Headquarters Maryland, U.S., North America
Recent Development In August 2024, an innovative fiber scaffold that enhances tissue engineering and cell production was the first commercial product of the University of Georgia firm CytoNest Inc., which debuted last month. The device, known as the CytoSurge 3D fiber scaffold, has uses in the generation of cultured meat and seafood, biopharmaceuticals, cell therapies, and cell research.

Innovation by Tempo Therapeutics in the Scaffold Technology Market

Company Name Tempo Therapeutics
Headquarters California, U.S., North America
Recent Development In September 2024, the first human study for Tempo Therapeutics' tissue regeneration product, TT101, began with patients who have had surgical resection. An integrative scaffold with the ability to regenerate soft tissue is called TT101. The clinical trial is being funded by proceeds from a $12 million Series A investment transaction that was obtained in March.

Tissue Repair Drives the Scaffold Technology Market

Number of Burn Injuries And Tts Treatment Each Year

Due to severe injuries that can occur due to accidents, burns, or other reasons, the human body is not able to repair tissues on its own, due to which tissue engineering using scaffold technology is used for tissue repair and tissue regeneration. Scaffolds provide a suitable and controllable environment for the growth and development of 3D tissue structures, which can be used to replace damaged tissues. The use of tissue engineering has recently increased for developing personalized therapeutics because the cells used for tissue repair are taken from the same person who is going to be used, which reduces the chances of graft rejection.

Scaffold-Free Cell Culture Restraint the Scaffold Technology Market

Scaffolds are essential for developing 3D tissue structure because they provide structure and a proper growth environment, and external factors can be controlled. However, due to the emerging scaffold-free cell culture technology, the demand for scaffolds is going down. There are several advantages of this technique, which is why researchers and healthcare professionals are inclined to use it. In order to increase the usage of scaffolds, researchers have to come up with solutions to mitigate the current faced by tissue engineers while using scaffolds.

Growing Whole Organ is the Future of the Scaffold Technology Market

Patients on the Waiting List By Organ in the U.S.

In the case of organ failure, organ donation has become the only way of saving lives. Every year, a lot of people wait to get organs, and every 8 minutes, another person is added to that list in the U.S. Despite waiting and continuous efforts, the chances of organ incompatibility or organ failure cannot be avoided. To avoid this, scaffold technology for developing whole organs can be used. Currently, there are many issues with this technique, but in the future, with technological advancements and with the help of AI and machine learning, better solutions can be developed that can be used for organ generation. Also, cells of the same person will be used, and then the organs will be highly compatible and personalized.

The Hydrogels Segment Dominated the Market in 2023

By type, the hydrogels segment held the majority of the scaffold technology market share in 2023. Hydrogels are similar to natural extracellular matrices when it comes to composition and structure. Hydrogels are also compatible with cell survival and proliferation. Due to these advantages, hydrogels are highly recommended for developing scaffolds. The use of hydrogels also mitigates the challenges such as vascularization. With the growing need for scaffold-based tissue engineering, the demand for hydrogels is also going to grow in the market.

For instance,

  • In December 2023, Metsä Spring is leading a seed fundraising round of EUR 1 million for FineCell, a Swedish firm that makes hydrogels and dry cellulose powder for paint, cosmetics, and healthcare goods.
  • In October 2023, PVA hydrogel microcarriers* were created by Kuraray Co., Ltd., specifically for use in regenerative medicine cell cultures. The product was introduced in January 2024, first in the US and then in Japan and other countries.

Fastest CAGR: The Nanofiber-Based Scaffolds Segment

By type, the nanofiber-based scaffolds segment is anticipated to grow at the fastest CAGR in the scaffold technology market during 2024-2034. The possibility of creating scaffolds that might be able to solve this issue has been substantially expanded by the creation of nanofibers. The possibilities for creating nanofibrous scaffolds have increased due to the abundance of both natural and manmade biomaterials. The possibility of creating scaffolds that may be able to replicate the structure of native human tissue at the nanoscale has increased with the creation of nanofibers.

For instance,

  • In July 2023, researchers discovered a method to employ nanotechnology to build a three-dimensional "scaffold" for the growth of retinal cells, opening the door to possible novel treatments for a frequent cause of blindness. This process, known as "electrospinning," has never before been utilized to build a scaffold on which the RPE cells may proliferate. If successful, it could completely change the way that age-related macular degeneration, one of the most prevalent eyesight problems in the world, is treated.

The Orthopedics, Musculoskeletal, And Spine Segment Dominated

By disease, the orthopedics, musculoskeletal, and spine segment dominated the scaffold technology market in 2023. It is estimated that there will be 4115046 hip fractures by the year 2050. Osteoporosis is a common issue that occurs due to old age, and more than 8.9 million people suffer from bone fractures due to osteoporosis. According to the WHO, around 1.71 billion people have musculoskeletal conditions across the globe, which is a leading cause of disability. People on a global level suffer from various health issues, such as fractures (440 million), low back pain (570 million), neck pain (222 million), osteoarthritis (528 million), amputations (180 million, gout (54 million), rheumatoid arthritis (18 million), and other musculoskeletal conditions (453 million).

With this growing number of bone-related injuries and health conditions, the need for scaffold technology for tissue engineering is in high demand. With the growing geriatric population, the number of bone-related issues is going to grow in the future.

Fastest Growth Rate: The Neurology Segment

The neurology segment is estimated to grow at the fastest rate in the scaffold technology market during the predicted period. Neural degeneration is a common issue in old people, which leads to various degenerative brain diseases like dementia, demyelinating diseases, Parkinson’s disease, motor neuron diseases, and prion diseases. Neural tissue engineering has great potential in repairing damaged nerve tissues. With growing potential in neurology, governments and key players are making investments in developing better treatment options using scaffold-based neural tissue engineering.

For instance,

  • The government of the UK decided to invest £375 million over the next five years from 2019-2024. The purpose of this investment was to improve the understanding and treatment of different neurodegenerative diseases.

The Stem Cell Therapy, Regenerative Medicine, And Tissue Engineering Segment Dominated

Investment in Stem Cell Research, By Product Type in the U.S., 2023 ($Millions)

By application, the stem cell therapy, regenerative medicine, and tissue engineering segment emerged as the dominant segment in the scaffold technology market in 2023. Stem cell therapy consists of growing stem cells in vitro via tissue engineering and then transferring them to the human body for therapeutic purposes. Because tissue engineering is a significant part of stem cell therapy, scaffolds are extensively used for growing stem cells. With the growing demand for precision and personalized medicine, stem cell therapy is also growing, which is positively impacting the market’s growth.

The Biotechnology & Pharmaceutical Companies Segment Dominated

By end-use, the pharmaceutical & biotechnology companies segment held the largest share of the scaffold technology market in 2023. Pharmaceutical and biotechnology companies are highly invested in developing new drugs and therapeutics. Scaffold technology helps in tissue engineering, which is further used for testing & developing new drugs, developing cell and gene therapies, and studying various systems of cells and organs. During the R&D and production, various tests are conducted on animal models and human cells. Scaffold technology helps researchers in companies develop 3D structures of organs, which helps in better understanding and reduces the usage of animal models.

Growing R&D Drives the North America’s Market

Stacked Graph 0

By region, North America dominated the scaffold technology market share by 43% in 2023. The U.S. and Canada are the major contributors to the market’s growth in North America. The U.S. government and key companies in the U.S. continuously invest in research and development in tissue engineering, biotechnology, pharmaceuticals, personalized medicine, therapeutics, and other sectors. Various regenerative medicine programs have been started in the U.S. that will support the growth of the scaffold technology market.

California Institute of Regenerative Medicine (CIRM) Case Study

The California Institute of Regenerative Medicine, which is the largest institution focusing on regenerative medicine, was awarded US$ 43.8 million for stem and gene therapy research. CIRM has 91 CIRM-funded clinical trials and 200+ clinical trials conducted at Alpha Clinics. CIRM has received more than US$ 24 billion in funding from pharmaceutical and biotechnology companies and also from other partnerships. More than 50 new startup businesses are associated with research projects that are funded by CIRM. Various diseases in which CRIM is involved are neurological disorders/injuries (35%), respiratory (6%), heart (3%), musculoskeletal (10%), cancer (20%), HIV/AIDS (3%), blood (6%), and eye (4%). For the fiscal year, a proper budget was allocated, which included US$ 252 million in clinical research, US$ 84.7 million in discovery research, and US$ 84.6 million in translational research.

Investments in Biotech & Pharma Drives Asia Pacific

Scaffold Technology Market NA, EU, APAC, LA, MEA Share, 2023 (%)

By region, Asia Pacific is expected to grow at the fastest rate during the forecast period. The government and various organizations in the Asia Pacific region are focusing on better healthcare and personalized therapeutics, due to which they are investing in the pharmaceutical and biotechnology industries. The major countries that contribute to the growth of the scaffold technology market are China, India, Japan, and South Korea. The growing population and various diseases in the region further promote the growth of the market.

China majorly contributes to the growth of the scaffold technology market due to the large presence of the biotechnology and pharmaceutical industries. In 2023, the health and pharmaceutical industry in Beijing reach CNY 980 billion. In Beijing, CNY 30 million in support was provided for gene therapy drugs and CNY 500,000 for biological products.

The Government is strongly investing in the research associated with regenerative medicine. Apart from this, various biotechnology and pharmaceutical companies are involved in the development of better healthcare. For instance, in 2022, there were 1390 new biotech startups in India. In 2022, the biopharma industry contributed US$ 49.8 billion to the bioeconomy of India.

Recent Developments in the Scaffold Technology Market

  • In July 2023, the two new CollaFibR tissue engineering products, CollaFibR (called micro-CollaFibR) and CollaFibRTM 3D scaffold, have been released, according to 3DBioFibR, a major developer in tissue engineering. The novel and exclusive dry-spinning process developed by 3D BioFibR is used to produce collagen fibers on a commercial scale in these off-the-shelf goods.
  • In June 2023, an animal-derived Class D Biomedical Device that may quickly mend skin wounds at a cheap cost with little scarring was approved by the Indian Drugs Controller. It is the first tissue engineering scaffold from mammalian organs to be produced nationally.

Segments Covered in the Report

By Type 

  • Hydrogels
  • Wound Healing
  • 3D Bioprinting
  • Immunomodulation
  • Nanofiber Based Scaffolds
  • Polymeric Scaffolds
  • Micropatterned Surface Microplates

By Disease

  • Orthopedics, Musculoskeletal & Spine
  • Neurology
  • Cancer
  • Skin & Integumentary
  • Dental
  • Cardiology & Vascular
  • Urology
  • GI, Gynecology
  • Others

By Application

  • Stem Cell Therapy, Regenerative Medicine & Tissue Engineering
  • Drug Discovery
  • Others

By End-Use

  • Biotechnology & Pharmaceutical Companies
  • Hospitals & Diagnostic Centers
  • Research Laboratories & Institutes
  • Others

By Region

  • North America
    • U.S.
    • Canada
  • Asia Pacific
    • China 
    • Japan
    • India
    • South Korea
    • Thailand
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Sweden
    • Denmark
    • Norway
  • Latin America
    • Brazil
    • Mexico
    • Argentina
  • Middle East and Africa (MEA)
    • South Africa
    • UAE
    • Saudi Arabia
    • Kuwait
  • Insight Code: 5235
  • No. of Pages: 150+
  • Format: PDF/PPT/Excel
  • Published: September 2024
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2022
  • Base Year: 2023
  • Estimated Years: 2024-2033

About The Author

Deepa has certified the degree of Master’s in Pharmacy in the Pharmaceutical Quality Assurance department from Dr D.Y. Patil College of Pharmacy. Her research is focused on the healthcare industry. She is the author or co-author of four Review Articles, which include Solid dispersion a strategic method for poorly soluble drugs and solubility improvement techniques for poorly soluble drugs, Herbal Drugs Used In Treatment Of Cataracts, Nano sponges And Their Application in Cancer Prevention and Ayurvedic Remedies of Peptic ulcer. She has also published a Research Article on the Formulation and Evaluation of Mucoadhesive Tablets of Miconazole cocrystal which was published in GIS Science Journal Volume 9 Issue 8. Her passion for secondary research and desire to take on the challenge of solving unresolved issues is making her flourish is the in the research sector.

FAQ's

Usually composed of polymeric biomaterials, scaffolds offer the structural backing necessary for cell adhesion and the subsequent formation of tissue.

In order to prevent loads, seismic activity, wind, and other outside factors from bending and eventually collapsing scaffolds, braces are essential.

Organ Donor.Gov, FDA, WHO, Department of Biotechnology, National Institutes of Health, National Library of Medicine, American Burn Association, HRSA. GOV.UK.